Today's Veterinary Practice

SEP-OCT 2018

Today's Veterinary Practice provides comprehensive information to keep every small animal practitioner up to date on companion animal medicine and surgery as well as practice building and management.

Issue link: https://todaysveterinarypractice.epubxp.com/i/1015043

Contents of this Issue

Navigation

Page 1 of 79

The FIRST AND ONLY FDA-approved transdermal medication for the management of weight loss in cats For more information, contact your KindredBio Sales Specialist at 1-888-608-2542, your preferred Distributor Sales Representative, or go to kindredbio.com/Mirataz. In clinical studies, Mirataz™ (mirtazapine transdermal ointment) resulted in significant weight gain in cats in as little as 14 days following topical application of 2 mg per day 1 Mirataz gives your clients a practical way to manage their cat's weight loss without administration of oral medication and does not rely on the cat to eat to be medicated Due to proprietary Accusorb™ technology, Mirataz achieves measurable plasma concentrations of mirtazapine in cats 2 Mirataz was well tolerated both locally and systemically in clinical studies 1 ✔ ✔ ✔ ✔ Reference: 1. Mirataz™ (mirtazapine transdermal ointment) [package insert], Kindred Biosciences, Inc. (Burlingame, CA). Rev. 5/2018. 2. Buhles W, Quimby JM, Labelle D, et al. Single and multiple dose pharmacokinetics of a novel transdermal ointment in cats. J Vet Pharmacol Ther. In press 2018. Important Safety Information Mirataz™ (mirtazapine transdermal ointment) is for topical use in cats only under veterinary supervision. Do not use in cats with a known hypersensitivity to mirtazapine or any of the excipients. Do not use in cats treated with monoamine oxidase inhibitors (MAOIs). Not for human use. Keep out of reach of children. Wear gloves when handling/applying, wash hands after and avoid contact between the treated cat and people or other animals for 2 hours following application. Use with caution in cats with hepatic and kidney disease. Cat's food intake should be monitored upon discontinuation. Safety has not been evaluated in cats less than 2 kg, less than six months of age or in breeding, pregnant or lactating cats. The most common adverse reactions observed during clinical trials were application site reactions, behavioral abnormalities (vocalization and hyperactivity) and vomiting. For additional safety information, see brief summary of prescribing information on following page. Mirataz™ and Accusorb™ are trademarks of KindredBio ©2 018 Kindred Biosciences, Inc., Burlingame, CA 94010. All rights reserved US-MAZ-1800044 May-11-2018 ANOTHER PILL? GIVE IT TO THE DOG. " " page 6.

Articles in this issue

Links on this page

Archives of this issue

view archives of Today's Veterinary Practice - SEP-OCT 2018